• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    INVO Fertility Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

    12/3/25 4:46:42 PM ET
    $IVF
    Medical/Dental Instruments
    Health Care
    Get the next $IVF alert in real time by email
    false --12-31 0001417926 0001417926 2025-11-26 2025-11-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported) November 26, 2025

     

    INVO FERTILITY, INC.

    (Exact name of registrant as specified in its charter)

     

    Nevada   001-39701   20-4036208

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

     

    5582 Broadcast Court

    Sarasota, FL 34240

    (Address of principal executive offices, including zip code)

     

    (978) 878-9505

    (Registrant’s telephone number, including area code)

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, $0.0001 par value   IVF   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

     

    On November 26, 2025, the Company filed a Certificate of Change (the “Certificate of Change”) with the Secretary of State of the State of Nevada to effectuate a 1-for-8 reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding and authorized shares of Common Stock. The Reverse Stock Split became effective at 12:01 a.m., Eastern Time, on Friday, November 28, 2025, and the Company’s Common Stock began trading on a split-adjusted basis when The Nasdaq Stock Market (“Nasdaq”) opened on November 28, 2025.

     

    When the Reverse Stock Split became effective, every 8 shares of Common Stock issued and outstanding were automatically reclassified and combined into one share of Common Stock, without any change in the par value per share, and a proportionate adjustment was made to the Company’s authorized shares of Common Stock such that the Company now has 6,250,000 shares of authorized Common Stock. In addition, a proportionate adjustment has been made to the per share exercise price and the number of shares issuable upon the exercise of all outstanding stock options and warrants to purchase shares of Common Stock and the number of shares reserved for issuance pursuant to the Company’s equity incentive compensation plans. No fractional shares of Common Stock were issued in connection with the Reverse Stock Split. Stockholders who otherwise would have been entitled to receive fractional shares of Common Stock had their holdings rounded up to the next whole share.

     

    The Company’s Common Stock will continue to trade on The Nasdaq Capital Market under the existing symbol “IVF”, but the security has been assigned a new CUSIP number (44984F807).

     

    The foregoing description of the Certificate of Change does not purport to be complete and is qualified in its entirety by reference to the full text of the Certificate of Change which is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.

     

    Item 8.01 Other Events

     

    On November 25, 2025, the Company issued a press release announcing the Reverse Stock Split. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit No.   Description
    3.1   Certificate of Change
    99.1   Press Release dated November 25, 2025
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document.)

     

    -2-

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: December 3, 2025 INVO FERTILITY, INC.
       
      /s/ Steven Shum
      Steven Shum
      Chief Executive Officer

     

    -3-

     

     

    Get the next $IVF alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IVF

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $IVF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Szot Matthew K sold $6 worth of shares (4 units at $1.52) and disposed of 3 shares, closing all direct ownership in the company (SEC Form 4)

    4 - INVO Fertility, Inc. (0001417926) (Issuer)

    12/5/25 9:40:32 PM ET
    $IVF
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chief Executive Officer Shum Steve

    4 - INVO Fertility, Inc. (0001417926) (Issuer)

    10/3/25 4:05:15 PM ET
    $IVF
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Ryan Barbara

    4 - INVO Fertility, Inc. (0001417926) (Issuer)

    8/28/25 9:18:42 PM ET
    $IVF
    Medical/Dental Instruments
    Health Care

    $IVF
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    INVO Fertility Announces Pricing of $4.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules

    SARASOTA, Fla., Dec. 02, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. ("INVO" or the "Company") (NASDAQ:IVF), a healthcare company focused on the fertility market, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 2,366,864 shares of common stock (or pre-funded warrants in-lieu thereof), together with warrants to purchase up to an aggregate 4,733,728 shares of common stock, in a private placement priced at-the-market under Nasdaq rules (the "Offering"). The combined effective offering price for each share of common stock (or pre-funded warrant in-lieu thereof) and accompanying warrants is $1.69. The warrants will have

    12/2/25 9:25:00 AM ET
    $IVF
    Medical/Dental Instruments
    Health Care

    INVO Fertility Announces Intent to Acquire Indiana-Based Fertility Clinic "Family Beginnings"

    SARASOTA, Fla. and INDIANAPOLIS, Nov. 28, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (NASDAQ:IVF) ("INVO" or the "Company"), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced its intent to acquire Family Beginnings, P.C., a respected fertility clinic serving patients across Indiana and the broader Midwest. The planned acquisition marks INVO's second acquisition after its purchase of Wisconsin Fertility Institute in 2023 and reflects the Company's multi-pronged strategic initiative to build a nationwide network of fertility centers capable of reaching underserved markets an

    11/28/25 1:05:00 PM ET
    $IVF
    Medical/Dental Instruments
    Health Care

    INVO Fertility Announces a 1:8 Reverse Stock Split Effective Pre-Market Opening on November 28, 2025

    SARASOTA, Fla., Nov. 25, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. ("INVO") (NASDAQ:IVF), a healthcare company focused on the fertility market, announced today that it will effect a 1-for-8 reverse split of its issued and outstanding and authorized common stock effective as of 12:01 a.m. Eastern Time on November 28, 2025. Commencing with the opening of trading on The Nasdaq Capital Market on November 28, 2025, the Company's common stock will trade on a post-split basis under the same trading symbol, "IVF". As a result of the reverse stock split, the CUSIP number for the Company's common stock will be 44984F807. As a result of the reverse stock split, every 8 shares of issued and outst

    11/25/25 9:00:00 AM ET
    $IVF
    Medical/Dental Instruments
    Health Care

    $IVF
    SEC Filings

    View All

    SEC Form PRE 14A filed by INVO Fertility Inc.

    PRE 14A - INVO Fertility, Inc. (0001417926) (Filer)

    12/8/25 5:21:12 PM ET
    $IVF
    Medical/Dental Instruments
    Health Care

    INVO Fertility Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

    8-K - INVO Fertility, Inc. (0001417926) (Filer)

    12/5/25 5:01:22 PM ET
    $IVF
    Medical/Dental Instruments
    Health Care

    INVO Fertility Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

    8-K - INVO Fertility, Inc. (0001417926) (Filer)

    12/3/25 4:46:42 PM ET
    $IVF
    Medical/Dental Instruments
    Health Care

    $IVF
    Leadership Updates

    Live Leadership Updates

    View All

    INVO Fertility Announces Intent to Acquire Indiana-Based Fertility Clinic "Family Beginnings"

    SARASOTA, Fla. and INDIANAPOLIS, Nov. 28, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (NASDAQ:IVF) ("INVO" or the "Company"), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced its intent to acquire Family Beginnings, P.C., a respected fertility clinic serving patients across Indiana and the broader Midwest. The planned acquisition marks INVO's second acquisition after its purchase of Wisconsin Fertility Institute in 2023 and reflects the Company's multi-pronged strategic initiative to build a nationwide network of fertility centers capable of reaching underserved markets an

    11/28/25 1:05:00 PM ET
    $IVF
    Medical/Dental Instruments
    Health Care

    $IVF
    Financials

    Live finance-specific insights

    View All

    INVO Fertility Announces 2024 Financial Results with 116% Annual Revenue Growth and Further Improvements in Adjusted EBITDA

    SARASOTA, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (NASDAQ:IVF) ("INVO Fertility" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment through the establishment, acquisition and operation of fertility clinics, today announced fourth quarter and full year 2024 financial results. Q4 2024 Financial Highlights (all metrics compared to Q4 2023 unless otherwise noted) Revenue was $1,685,966, an increase of 22% compared to $1,381,754.Consolidated clinic revenue from the Company's INVO Center in Atlanta, Georgia, and fertility clinic in Madison, Wisconsin increased 24% to $1,687,300, compared to $1,362,938.Revenue from

    4/30/25 9:00:49 AM ET
    $IVF
    Medical/Dental Instruments
    Health Care